Arena Pharmaceuticals, Inc.  

(Public, NASDAQ:ARNA)   Watch this stock  
Find more results for arna
+0.01 (0.74%)
After Hours: 1.44 +0.07 (5.11%)
Jan 20, 4:43PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.34 - 1.40
52 week 1.32 - 2.16
Open 1.35
Vol / Avg. 1.87M/1.79M
Mkt cap 330.91M
P/E     -
Div/yield     -
EPS -0.38
Shares 243.31M
Beta -0.68
Inst. own 51%
Feb 27, 2017
Q4 2016 Arena Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 12, 2017
Arena Pharmaceuticals Inc at JPMorgan Healthcare Conference
Nov 29, 2016
Arena Pharmaceuticals Inc at Piper Jaffray Healthcare Conference
Nov 7, 2016
Q3 2016 Arena Pharmaceuticals Inc Earnings Call
Nov 7, 2016
Q3 2016 Arena Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -64.85% -281.74%
Operating margin -51.23% -269.26%
EBITD margin - -232.70%
Return on average assets -23.38% -40.50%
Return on average equity -587.01% -214.06%
Employees 228 -
CDP Score - -


6154 Nancy Ridge Dr
SAN DIEGO, CA 92121-3223
United States - Map
+1-858-4537200 (Phone)
+1-858-4537210 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that target G protein-coupled receptors (GPCRs). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management, and is being commercialized under the brand name, BELVIQ. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. APD334 is an orally available modulator of the sphingosine 1-phosphate subtype 1 (S1P1) receptor intended for the treatment of multiple sclerosis, psoriasis, inflammatory bowel diseases and rheumatoid arthritis. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases and an undisclosed orphan GPCR for central nervous system indication(s).

Officers and directors

Amit D. Munshi President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Kevin R. Lind Chief Financial Officer, Principal Financial Officer, Executive Vice President, Principal Accounting Officer
Age: 40
Bio & Compensation  - Reuters
Steven W. Spector J.D. Executive Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Vincent E. Aurentz Executive Vice President and Chief Business Officer
Bio & Compensation  - Reuters
Craig M. Audet Ph.D. Senior Vice President - Operations and Head of Global Regulatory Affairs
Age: 51
Bio & Compensation  - Reuters
Jennifer Kathleen Bielasz Vice President - Accounting, Controller
Age: 52
Bio & Compensation  - Reuters
Christine Anna White M.D. Lead Independent Director
Age: 63
Bio & Compensation  - Reuters
Harry F. Hixson Jr. Ph.D. Director
Age: 77
Bio & Compensation  - Reuters
Donald D. Belcher Independent Director
Age: 76
Bio & Compensation  - Reuters
Scott H. Bice Independent Director
Age: 68
Bio & Compensation  - Reuters